Cristina Churruca

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Bradley J. Monk, Rachel N. Grisham, Susana Banerjee et al. · Journal of Clinical Oncology · 2020 · 153 citations · Full text

Medicine, Oncology, Pharmacology +17

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

Jean‐Emmanuel Kurtz, Éric Pujade-Lauraine, Ana Oaknin et al. · Journal of Clinical Oncology · 2023 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

Alexander Olawaiye, Laurence Gladieff, David M. O’Malley et al. · The Lancet · 2025 · 46 citations

Medicine, Oncology, Pharmacology +13

Factors that Influence Treatment Delay for Patients with Breast Cancer

María Padilla-Ruiz, Irene Zarcos‐Pedrinaci, Francisco Rivas‐Ruiz et al. · Annals of Surgical Oncology · 2020 · 26 citations

Medicine, Oncology, Breast Oncology +12

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, Ignace Vergote, Susana Banerjee et al. · Clinical Cancer Research · 2023 · 22 citations · Full text

Medicine, Oncology, Pharmacology +17